> Schering-Plough announced that five patients taking its experimental AIDS therapy vicriviroc contracted cancer but added that no causal relationship had been established. Report
> Shares of Cubist Pharmaceuticals dropped on Friday as investors braced for an FDA advisory meeting today on whether to expand use of Cubicin antibiotic. Report
> Researchers presented new Phase III data demonstrating the safety and efficacy of Vivaglobin for treating patients with primary immunodeficiency. Release
> Corgentech announced that the lowest dosage of its Avrina eczema therapy proved the most effective. Report
> Millennium Pharmaceuticals and Johnson & Johnson have launched a Phase II trial of Velcade for injection in non small cell lung cancer. Release
> Late last week Kosan Biosciences cut 39 jobs as part of a restructuring. Report
> Mannkind has launched two Phase III trials for Technosphere Insulin in patients with Type 1 and Type 2 Diabetes. Release
> Health Canada has approved Aurobindo Pharma's Citalopram Hydrobromide tablets 20 mg and 40 mg. Release
> China Health Holding has entered into a letter of intent to acquire 51 percent or more of Shaanxi Wanan Pharmaceutical. Release
And Finally... Under pressure, giant retailer Wal-Mart has agreed to carry the controversial Plan B contraceptive. Report